Concord Biotech Ltd IPO

MidcapPharmaceuticalsMainboard

IPO Details

Bidding Dates

04 Aug '23 - 08 Aug '23

Minimum Investment

₹14,820 / 1 Lots (20 Shares)

Price Range

₹705 - ₹741

Maximum Investment

₹192,660 / 13 Lots (260 Shares)

Retail Discount

Not Applicable

Issue Size

₹1,551 Cr

Investor category and sub category

Qualified Institutional Buyers | Non-Institutional Investors | Retail Individual Investors | Employees

Concord Biotech IPO Dates

Important dates with respect to IPO allotment and listing

IPO Opening Date

Aug 4, 23

IPO Closing Date

Aug 8, 23

Basis of Allotment

Aug 11, 23

Initiation of Refunds

Aug 14, 23

Credit of Shares to Demat Account

Aug 17, 23

IPO Listing Date

Aug 18, 23

UPI Mandatory Expiry Date

Aug 8, 23

Concord Biotech IPO Subscription Details

Date	QIB	EMP	NII	Retail	Total
Day 1Aug 4 2023	0.00	3.80	0.35	0.38	0.27

About Concord Biotech Ltd

Concord Biopharma started its operations in 2016 and is a leading Indian pharma company engaged in manufacturing selected fermentation-based APIs (Active Pharmaceutical Ingredients) for immunosuppressants and oncology drugs. Concord Biopharma exports to more than 70 countries in the USA, Europe, Japan, Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore, Paraguay, and India. It has established a successful, backwards-integrated, scalable business model. The company is one of the few companies to produce six fermentation-based immunosuppressant APIs.

Concord Biotech is expanding to include anti-fungal and oncology drug APIs.

Concord Biotech Ltd IPO Details

Concord Biotech is a 100% offer for sale worth ₹1,551.00 crore. The issue comprises 20,925,652 shares and is priced at ₹705 to ₹741 per share. Retail investors can bid for the Concord Biotech Limited IPO, which will open on August 4, 2023. Concord Biotech Limited’s IPO will list on the BSE and NSE exchanges on August 18, 2023.

Concord Biotech Ltd IPO Objective

To achieve the benefits of listing on the stock exchanges
To carry out the offer for sale of up to 20,925,652 shares

Noteworthy Highlights Of Concord Biotech Ltd

As of March 31, 2022, the annual installed capacity for formulation manufacturing was 522.64 million units.
The company caters to 200 customers in 70 countries and offers a diversified product portfolio of 27 brands across immunosuppressant API, nephrology, anti-fungal, anti-infective, oncology, and critical care drugs APIs.

Competitive Peers

Other listed players in the segment recognised by Concord Biotech Ltd are Divi’s Laboratories, Suven Pharmaceuticals, Laurus Labs, and Shilpa Medicare.

Concord Biotech Ltd Company Financials

Particulars	March 31, 2023 (₹ in million)	March 31, 2022 (₹ in million)
Total Income	8,884.77	7,363.49
Profit After Tax (PAT)	2,400.84	1,749.29
Net Worth	12,900.01	11,032.23
Earnings Per Share	22.95	16.72
Total Borrowings	312.36	605.86

Know before investing

Strengths

The net worth of the company increased from ₹9,993.73 million on March 31, 2021, to ₹12,900.01 million on March 31, 2023.
Concord Biopharma is a leader in its segment with a 20% market share in 2022, in terms of volume.

Risks

Concord Biotech’s revenue is dependent on limited customers and any interruption in the client’s demand can adversely impact the company’s revenue.
If the company is not able to obtain trademarks and patents for their products, the business can get impacted.

How to Apply in IPO
How to Check IPO Allotment Status

Select desired IPO & tap on "Apply"

Enter UPI ID, set quantity/price & submit

Accept mandate on the UPI app to complete the process

Concord Biotech Ltd IPO FAQs

What is Concord Biotech Limited's IPO?

The Concord Biotech Ltd IPO is 100% Offer for Sale IPO worth ₹1,551 crore. The issue comprises 20,925,652 shares and is priced at ₹705 to ₹741 per share. The IPO will open on August 4, 2023.